Amgen purchases Tularik for 1.3 Billion US$
It was announced that the deal would increase the research and development costs by 100 million dollars per year. The prognosis for Amgen in 2004 remains unchanged with a profit of $ 2.30 - $2.40 per share. Tularik, located in southern San Francisco, is a pioneer in the field of pharmaceutical development based on cell signalization and gene expression.
The only thing that will change for Tularik Deutschland GmbH, which has been based in BioPark Regensburg since 2000, is its name. In the future the company will continue its development of new cellular and biochemical testing systems (Assays) for new compounds. The strength of the German branch of the company lies specifically in the screening of lower molecular substances in an automated high-throughput-screen; this is necessary for the identification of pharmacologically effective lead-substances. According to BioPark Regensburg GmbH the Regensburg location is set to grow. The ground breaking ceremony for the second phase of construction (BioPark II) occurred on April 22, 2004. The new construction will make it possible for successful companies to expand here in the same location. The middle and long term development foresees the establishment of a TechnologyPark Regensburg.
For more information see: